You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 135 No. 7, July 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (18)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Gastrointestinal Diseases
 •Oncology, Other
 •Alert me on articles by topic

Adenocarcinoma of the Esophagus With and Without Barrett Mucosa

Michael S. Sabel, MD; Kate Pastore, MD; Hannah Toon, MD; Judy L. Smith, MD

Arch Surg. 2000;135:831-836.

Hypothesis  Previous studies have demonstrated an improved prognosis in patients with Barrett adenocarcinoma as compared with esophageal adenocarcinoma without Barrett. It has been suggested that an earlier presentation due to gastroesophageal reflux disease (GERD) may lead to detection of adenocarcinoma at an earlier stage.

Design  The records of 178 patients with esophageal adenocarcinoma presenting to Roswell Park Cancer Institute (Buffalo, NY) between 1991 and 1996 were reviewed.

Main Outcome Measures  The clinical presentation, work-up, therapy, and outcome were compared between patients with Barrett esophagus (n=66) and those without endoscopic or pathologic evidence of Barrett esophagus (n=112).

Results  There were several favorable prognostic signs in the Barrett group, including smaller tumors, lower grade, and earlier stage. More patients in the Barrett group had surgically resectable tumors, resulting in an improved overall survival. However, there were no differences in the type or duration of symptoms. Overall, very few patients presented because of GERD, and only slightly more in the Barrett group (14% vs 4%). While survival greatly improved in patients diagnosed with Barrett due to GERD, this did not account for the difference in prognosis.

Conclusions  Improved prognosis and survival for the Barrett group is not due to earlier presentation due to symptoms of GERD. It is more likely that all esophageal adenocarcinoma arises from Barrett esophagus, and that it is obscured by larger tumors. Reviews limited to resected patients greatly overestimate the number of adenocarcinoma cases diagnosed due to GERD. Increased efforts to identify high-risk patients and initiate screening are necessary to diagnose adenocarcinoma at an earlier stage.


From the Roswell Park Cancer Institute, Buffalo, NY.


RELATED ARTICLE

Adenocarcinoma of the Esophagus With and Without Barrett Mucosa—Invited Critique
Jeffrey H. Peters
Arch Surg. 2000;135(7):836.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Comparison of the Clinical and Histological Characteristics and Survival of Distal Esophageal-Gastroesophageal Junction Adenocarcinoma in Patients With and Without Barrett Mucosa
Portale et al.
Arch Surg 2005;140:570-575.
ABSTRACT | FULL TEXT  

Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett's Esophagus and Symptomatic Gastroesophageal Reflux
Agarwal et al.
Ann. Thorac. Surg. 2005;79:1716-1723.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.